Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma / 전남의대학술지
Chonnam Medical Journal
;
: 25-30, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-719479
ABSTRACT
This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6.75 mg/m² on days 1–4, once-weekly dose of oral cyclophosphamide 300 mg/m2 and dexamethasone 20 mg/m² on days 1–4 and days 15–18. Each cycle was repeated every 28 days. The median age of the patients was 66 years and the MCD regimen was initiated at a median 37.7 months from diagnosis. Patients received a median of five regimens including autologous stem cell transplantation. The overall response rate was 25.9% (very good partial response 3.7%, partial response 22.2%) and 8 (29.6%) patients achieved a minor response. Median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2–8.5) ; overall survival 11.7 months (95% CI, 5.4–16.6). Grade 3 or 4 neutropenia and thrombocytopenia were observed in 51.8% and 33.3%, respectively. Although the overall response rate is relatively low, the MCD regimen may have a role as a bridge to a novel regimen in heavily pretreated patients with MM.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Trombocitopenia
/
Dexametasona
/
Estudios Retrospectivos
/
Terapia Recuperativa
/
Supervivencia sin Enfermedad
/
Ciclofosfamida
/
Trasplante de Células Madre
/
Diagnóstico
/
Melfalán
/
Mieloma Múltiple
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
Límite:
Humanos
Idioma:
Inglés
Revista:
Chonnam Medical Journal
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS